Chorulon 1500 IU Powder and Solvent for Solution for Injection

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Chorionic Gonadotrophin

Available from:

MSD Animal Health UK Limited

ATC code:

QG03GA01

INN (International Name):

Chorionic Gonadotrophin

Pharmaceutical form:

Powder and solvent for solution for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cattle, Dogs, Horses

Therapeutic area:

Hormone sex

Authorization status:

Authorized

Authorization date:

1994-05-18

Summary of Product characteristics

Revised: April 2021
AN: 02063/2020
Page 1 of 6
SUMMARY OF PROUDCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Chorulon 1500 iu, powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial of active contains:
_Active substance:_
Chorionic gonadotrophin
1500 iu
Each vial of solvent contains 5 ml of a sterile buffered solvent for
reconstitution.
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection
White powder and clear colourless solution.
Reconstituted solution is colourless.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, horses and dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product can be used in the following fertility problems in
domestic
animals:
-
cases of repeated failure of conception in cows and heifers
-
induction of ovulation in mares and bitches
-
cases of cystic ovaries in cows and heifers
-
anoestrus in mares and bitches
-
delayed ovulation, prolonged pro-oestrus in bitches
-
deficiency in libido in male dogs
4.3
CONTRA-INDICATIONS
None
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
None
Revised: April 2021
AN: 02063/2020
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
(i)
Special precautions for use in animals
None
(ii)
Special
precautions
to
be
taken
by
the
person
administering
the
medicinal product to the animals
Care should be taken to avoid accidental self-injection; if accidental
self-
injection occurs, seek medical advice immediately and show the doctor
this label.
Wash hands after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
In rare cases, as with all protein preparations, anaphylactoid
incidents
may occur shortly after injection. Adrenalin injection (1:1,000) given
intravenously or intramuscularly when symptoms appear is the standard
treatment. The administration of corticosteroids may also be
indicated.
4.7
USE DURING PREGNANCY OR LACTATION
Not applicable
4.8
INTERACTION
WITH
OTHER
MEDICINAL
PRODUCTS
AND
OTHER
FORMS
OF
INTERACTION
None
4.9
AMOUNTS T